Cangene

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Cangene Corporation was a pharmaceutical/biopharmaceutical company based in Winnipeg. Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. The company operates eight locations across North America and employs over 600 mostly in Winnipeg or in Baltimore at Cangene bioPharma (which is responsible for contract manufacturing).[1]

Cangene is 61% owned by Canadian pharmaceutical giant Apotex and has many collaborative agreements with them. The company was listed on the TSX under the symbol CNJ.

In 2013, the company purchased rights to development and commercialization of three drug candidates, recombinant blood clotting factors VIIa, VIII and IX, the latter of which is in clinical trials.[2]

In February 2014, the company was acquired by Emergent BioSolutions.[3]

References[edit]

  1. ^ "[1]." Cangene. Retrieved on 5 Aug 2013.
  2. ^ Cangene inks $300+M deal for bankrupt Inspiration's IB1001, Genetic Engineering & Biotechnology News (paper ed.) 33 (6), March 15, 2013: 8 
  3. ^ Press Release (21 February 2014). "Emergent BioSolutiions Completes Acquisition of Cangene Corporation". Emgergent Biosolutions. Retrieved 17 June 2014. 

External links[edit]